Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Formula | C30H30Cl2N4O4 |
|||
Molecular Weight | 581.49 | CAS No. | 675576-98-4 | |
Solubility (25°C)* | In vitro | DMSO | 100 mg/mL (171.97 mM) | |
Ethanol | 100 mg/mL (171.97 mM) | |||
Water | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
Description | Nutlin-3a ((-)-Nutlin-3), the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner. | ||
---|---|---|---|
Targets |
|
||
In vitro | Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1]. | ||
In vivo | Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a. | ||
Features | Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53. |
Kinase Assay:[3] |
|
---|---|
Cell Assay:[2] |
|
Animal Study:[1] |
|
|
, , J Cell Mol Med, 2017, 21(12):3435-3444
Data from [Data independently produced by , , Oncogene, 2016, 35(42):5552-5564]
Data from [Data independently produced by , , Int J Cancer. 2019, 144(4):777-787]
Data from [Data independently produced by , , Cancer Lett, 2016, 381(2):370-9]
SPOCK2 modulates neuropathic pain by interacting with MT1-MMP to regulate astrocytic MMP-2 activation in rats with chronic constriction injury [ J Neuroinflammation, 2024, 21(1):57] | PubMed: 38388415 |
Integrated drug response prediction models pinpoint repurposed drugs with effectiveness against rhabdomyosarcoma [ PLoS One, 2024, 19(1):e0295629] | PubMed: 38277404 |
A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO [ bioRxiv, 2024, 2024.01.20.576487.] | PubMed: 38328189 |
Histone H3 lysine 27 crotonylation mediates gene transcriptional repression in chromatin [ Mol Cell, 2023, 83(13):2206-2221.e11] | PubMed: 37311463 |
The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells [ Cell Death Differ, 2023, 30(4):1033-1046] | PubMed: 36739334 |
p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma [ Exp Hematol Oncol, 2023, 12(1):28] | PubMed: 36882855 |
Differences in syncytia formation by SARS-CoV-2 variants modify host chromatin accessibility and cellular senescence via TP53 [ Cell Rep, 2023, 42(12):113478] | PubMed: 37991919 |
SPINK2 Protein Expression Is an Independent Adverse Prognostic Marker in AML and Is Potentially Implicated in the Regulation of Ferroptosis and Immune Response [ Int J Mol Sci, 2023, 24(11)9696] | PubMed: 37298647 |
Cytoplasmic localization of Mdm2 in cells expressing mutated NPM is mediated by p53 [ FEBS J, 2023, 10.1111/febs.16810] | PubMed: 37119456 |
Characterizing the secretome of EGFR mutant lung adenocarcinoma [ Front Oncol, 2023, 13:1286821] | PubMed: 38260835 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.